Eisai Korea Inc.
Clinical trials sponsored by Eisai Korea Inc., explained in plain language.
-
New study tracks Real-World safety of arthritis and colitis drug in korea
Disease control Recruiting nowThis study is monitoring the safety and effectiveness of the drug Jyseleca (filgotinib) in Korean patients with rheumatoid arthritis or ulcerative colitis. Researchers will track side effects and disease activity over 24 weeks. About 2,040 participants are being observed during r…
Sponsor: Eisai Korea Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New pill aims to calm ulcerative colitis flare-ups in korean patients
Disease control Recruiting nowThis study tests a daily medication called filgotinib (200 mg) in about 94 Korean adults with moderate-to-severe ulcerative colitis. The main goal is to see if it can bring the disease into remission (no active symptoms) by week 10 or 22. Participants take the pill once daily and…
Phase: PHASE4 • Sponsor: Eisai Korea Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Alzheimer's drug LEQEMBI under 6-Year safety watch in 3,000 patients
Disease control Recruiting nowThis study will follow 3,000 South Korean Alzheimer's patients taking LEQEMBI for up to 6 years to monitor safety, especially brain swelling or bleeding. Researchers will use real-world data from a national registry. The goal is to understand how often these side effects occur in…
Sponsor: Eisai Korea Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC